This federal contract award, valued at $741,236.00, was issued by the Defense Health Agency to the prime contractor, George Mason University, for Compound Assessment Research Support. The contract is a Definitive Contract with a Firm Fixed Price pricing type. No set-aside designation was used.
George Mason University, a large public research university in Virginia, will be conducting scientific research and development work for the Department of Defense under this contract. The work includes synthesizing libraries of compounds to develop structure-activity relationships for peptide derivatives with antibiotic activity, and ultimately producing large quantities of lead compounds for in vivo studies. A subcontract has been awarded to Covenant Therapeutics LLC, a minority-owned small business, to support this effort.
This contract award appears to be part of the Defense Health Agency's broader mission to advance medical capabilities and therapeutics for warfighters and the military healthcare system. George Mason University has a strong track record of providing scientific research, engineering, and technology development services to various federal agencies through both contracts and grants.
Generated 10/14/24, 10:08 AM